Low circulating level of CD133+KDR+cells in patients with systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 62, 2010, Pages

  Mok, M Y ^a   Yiu, K H ^a   Wong, C Y ^a   Qiuwaxi, J ^a   Lai, W H ^a   Wong, W S ^a   Tse, H F ^a   Lau, C S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Disease activity; Endothelial dysfunction; Endothelial progenitor cells; Systemic sclerosis

Indexed keywords

C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CD133 ANTIGEN; CD34 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENICILLAMINE; PREDNISOLONE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; VASODILATATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; PEPTIDES; REGIONAL BLOOD FLOW; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SEVERITY OF ILLNESS INDEX; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASODILATION;

EID: 78650557653     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. KAHALEH MB: Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 2004;16:718-22.
2. LeROY EC: Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
3. ANDERSEN GN, MINCHEVA-NILSSON L, KAZZAM E et al.: Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 2002;46:1324-32.
4. ALLANORE Y, BATTEUX F, AVOUAC J, ASSOUS N, WEILL B, KAHAN A: Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 2007;25:60-6.
5. FREEDMAN RR, GIRGIS R, MAYES MD: Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 1999;26:2386-8. (Pubitemid 29528978)
6. LA CIVITA L, ROSSI M, VAGHEGGINI G et al.: Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. Ann Rheum Dis 1998;57:52-5.
7. SHANTSILA E, WATSON T, TSE HF, LIP GY: New insights on endothelial progenitor cell subpopulations and their angiogenic properties. J Am Coll Cardiol 2008;51:669-71.
8. TAKAHASHI T, KALKA C, MASUDA H et al.: Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-8. (Pubitemid 29180584)
9. HRISTOV M, WEBER C: Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004;8:498-508.
10. SHINTANI S, MUROHARA T, IKEDA H et al.: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001;103:2776-9.
11. WERNER N, KOSIOL S, SCHIEGL T et al.: Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007. (Pubitemid 41262334)
12. NEVSKAYA T, BYKOVSKAIA S, LYSSUK E et al.: Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol 2008;26:421-9.
13. DEL PAPA N, COLOMBO G, FRACCHIOLLA N et al.: Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004;50:1296-304.
14. KUWANA M, OKAZAKI Y, YASUOKA H, KAWAKAMI Y, IKEDA Y: Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-10.
15. AVOUAC J, JUIN F, WIPFF J et al.: Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 2008;67:1455-60.
16. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
17. DEL PAPA N, QUIRICI N, SOLIGO D et al.: Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006;54:2605-15.
18. VALENTINI G, DELLA ROSSA A, BOMBARDIERIS et al.: European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8. (Pubitemid 32493986)
19. VALENTINI G, BENCIVELLI W, BOMBARDIERI S et al.: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3. (Pubitemid 37026505)
20. CORRETTI MC, ANDERSON TJ, BENJAMIN EJ et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
21. IP MS, TSE HF, LAM B. TSANG KW, LAM WK: Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med 2004;169:348-53.
22. LAU KK, CHAN YH, YIU KH et al.: Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension. J Hum Hypertens 2007;21:445-51.
23. LUTTUN A, CARMELIET G, CARMELIET P: Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 2002;12:88-96.
24. DISTLER O, DEL ROSSO A, GIACOMELLI R et al.: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4: R11.
25. CHOI JJ, MIN DJ, CHO ML et al.: Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003;30:1529-33.
26. AVOUAC J, WIPFF J, GOLDMAN O et al.: Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum 2008;58:3550-61.
27. CIPRIANI P, GUIDUCCI S, MINIATI I et al.: Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007;56:1994-2004.
28. DREXLER H, HORNIG B: Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999;31:51-60.
29. LEKAKIS J, PAPAMICHAEL C, MAVRIKAKIS M, VOUTSAS A, STAMATELOPOULOS S: Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol 1998;82:1555-7, A8.
30. LEKAKIS J, MAVRIKAKIS M, PAPAMICHAEL C et al.: Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998;136:905-12.
31. MOK MY, FUNG PC, OOIC et al.: Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. Clin Rheumatol 2008;27:315-22.
32. ANDERSEN GN, CAIDAHL K, KAZZAM E et al.: Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000;43:1085-93.
33. GEHLING UM, ERGUN S, SCHUMACHER U et al.: In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106-12.
34. FRIEDRICH EB, WALENTA K, SCHARLAU J, NICKENIG G, WERNER N: CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circulation Res 2006;98: e20-5.
35. DISTLER JH, ALLANORE Y, AVOUAC J et al.: EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis 2009;68:163-8.
36. ROBB AO, MILLS NL, SMITH IB et al.: Influence of menstrual cycle on circulating endothelial progenitor cells. Hum Reprod (Oxford) 2009;24:619-25.
37. BHADAURIA S, MOSER DK, CLEMENTS PJ et al.: Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol 1995;172:580-7.
38. NEVSKAYA T, ANANIEVA L, BYKOVSKAIA S et al.: Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology (Oxford) 2009;48:61-4.
39. KUWANA M: Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol 2006;18:594-600.
40. HUANG P, LI S, HAN M, XIAO Z, YANG R, HAN ZC: Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005;28:2155-60.
41. KANG HI, KIM HS, ZHANG SY et al.: Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004;363:751-6.